Pharmaceuticals News and Research

RSS

Par Pharmaceutical reports total revenues of $1,193.2 million for 2009

Par Pharmaceutical Companies, Inc. today reported results for the fourth quarter and full year ended December 31, 2009.

24 Feb 2010

BioMarin Pharmaceutical reports GAAP net income of $4.7M for fourth-quarter 2009

BioMarin Pharmaceutical Inc. today announced financial results for the fourth quarter and year ended December 31, 2009. GAAP net income was $4.7 million ($0.05 per diluted share) for the fourth quarter of 2009, compared to GAAP net income of $24.5 million ($0.21 per diluted share) for the fourth quarter of 2008, which included a $30.0 million payment from Merck Serono related to the approval of Kuvan in the EU.

24 Feb 2010

Elsevier shares internal custom publication guidelines with scientific and medical communities

Elsevier, the world's leading publisher of scientific, technical and medical (STM) information products and services announced today that it is publicly sharing its internal custom publication guidelines so that the scientific and medical communities can have insight into a new and practical set of publishing standards for producing custom and sponsored publications.

24 Feb 2010

BioStorage Technologies' Frankfurt facility receives green certification from ENTEGA Vertrieb

BioStorage Technologies, a worldwide provider of long- and short-term storage of biomaterials, sample management and cold chain logistics, today announced its full-service biorepository near Frankfurt, Germany received green certification from ENTEGA Vertrieb GmbH & Co., a leading Germany-based sustainable energy supplier.

24 Feb 2010

Diabetic Neuropathy: Drug having disease-modifying potential will earn 40% patient share in the U.S

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of diabetic neuropathy, a drug that has disease-modifying potential would earn 40 percent patient share in the U.S., according to surveyed U.S. neurologists. Similarly, in Europe, such a drug would earn a comparable patient share of 43 percent, according to surveyed European neurologists.

24 Feb 2010

Fresenius Medical Care fourth-quarter net revenue up 12%

Fresenius Medical Care AG & Co. KGaA, the world’s largest provider of dialysis products and services, today announced its results for the fourth quarter and full year of 2009.

24 Feb 2010

Nominations accepted for 2010 George Washington Carver Award

The third annual George Washington Carver Award will recognize significant contributions by an individual to the field of industrial biotechnology, including applications in biological engineering, environmental science, biorefining and biobased products. The Biotechnology Industry Organization today announced that it is accepting nominations for the 2010 George Washington Carver Award, which will be presented at the 2010 World Congress on Industrial Biotechnology and Bioprocessing, June 27-30, 2009 in Washington, D.C.

24 Feb 2010

Emerging oral atypical antipsychotics to compete in increasingly crowded schizophrenia drug market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the world's major pharmaceutical markets, emerging oral atypical antipsychotics will compete against each other and against established drugs for the same niche patient population in the treatment of schizophrenia.

24 Feb 2010

Sentry BioPharma Services to warehouse and distribute influenza vaccines for CDC

Sentry BioPharma Services announced today that The Centers for Disease Control & Prevention (CDC) selected Sentry to store and distribute influenza vaccine in support of its national strategic reserve. Sentry will warehouse and distribute vaccine from its cGMP, FDA-registered facility located in Indianapolis, Ind. Sentry's vast experience storing and transporting regulated, temperature-sensitive pharmaceutical products will ensure product integrity, supply chain security and fast, efficient distribution of the disease-preventing vaccines.

24 Feb 2010

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

Idera Pharmaceuticals, Inc. today presented data on the mechanism of action of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, in a preclinical primate model at the Keystone Symposia conference “Tolerance and Autoimmunity” being held February 21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the treatment of autoimmune diseases. The presentation entitled “IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates” was made by Idera scientists.

24 Feb 2010

FEHBP PBM contracts: HR 4489 to reduce fraud and grant OPM greater power to audit

The House Subcommittee for the Federal Workforce, Postal Service, and the District of Columbia heard testimony today on HR 4489, the “FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act.” The proposed bill would reform many aspects of how the Federal Employee Health Benefits Program (FEHBP) contracts with pharmacy benefit managers (PBMs) to provide prescription drug benefits to federal workers.

24 Feb 2010

PAREXEL International expands capabilities by opening new early phase unit in Port Elizabeth, South Africa

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has expanded its capabilities through the opening of a new early phase unit in Port Elizabeth, South Africa.

From Parexel 24 Feb 2010

UK pharmacists overwhelmingly prefer dispensing preservative-free drugs

MeadWestvaco Corp. announced today results from an online survey of 100 pharmacists in the UK regarding their preference for dispensing preservative-free nasal medications. The survey showed that 67 percent of UK pharmacists have a preference for dispensing a preservative-free drug. This percentage increased significantly to 84 percent after the benefits of preservative-free drugs were reviewed with these pharmacists.

24 Feb 2010

Poniard Pharmaceuticals enters into $20M committed equity financing facility with Commerce Court Small Cap Value Fund

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that it has entered into a committed equity financing facility under which it may sell up to $20 million of its registered common stock to Commerce Court Small Cap Value Fund, Ltd. over an approximately 18-month period. Poniard is not obligated to utilize any of the facility and remains free to enter into other financing transactions.

24 Feb 2010

Medical innovation: A real boon for American patients

An article in the Journal Miner recently highlighted the fact that many people are living longer, healthier and more productive lives thanks to medical innovation and research.

24 Feb 2010

Watson Pharmaceuticals' fourth-quarter net revenue rises 22%

Watson Pharmaceuticals, Inc. today reported net revenue for the fourth quarter ended December 31, 2009 climbed 22 percent to $785.7 million, compared to $645.2 million in the fourth quarter 2008.

24 Feb 2010

Tenet Healthcare announces 9.0% increase in fourth-quarter EBITDA

Tenet Healthcare Corporation today reported adjusted EBITDA of $218 million for the fourth quarter ended Dec. 31, 2009, an increase of $18 million, or 9.0 percent, as compared to $200 million for the fourth quarter of 2008.

24 Feb 2010

CellCentric out-licenses development, commercialisation of novel epigenetic discovery programme to Takeda Pharmaceutical

From its broad portfolio of novel targets in epigenetics, CellCentric has out-licensed exclusively the development and commercialisation of an important programme focused on cancer.

24 Feb 2010

WuXi PharmaTech's Shanghai c-GMP manufacturing facility receives MPA compliance certificate

WuXi PharmaTech (WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it received the formal certificate of GMP compliance from the Medical Products Agency (MPA) of Sweden, acting on behalf of the European Medicines Agency (EMEA), for its c-GMP drug product manufacturing and analytical testing facilities located in Shanghai.

24 Feb 2010

Clout of drug industry seen in MD residency programs and in health reform

News outlets report on the pharmaceutical industry's involvement in doctor training and its role in shaping the health care overhauls pending in Congress.

24 Feb 2010

Pharmaceuticals News and Research

Par Pharmaceutical reports total revenues of $1,193.2 million for 2009

BioMarin Pharmaceutical reports GAAP net income of $4.7M for fourth-quarter 2009

Elsevier shares internal custom publication guidelines with scientific and medical communities

BioStorage Technologies' Frankfurt facility receives green certification from ENTEGA Vertrieb

Diabetic Neuropathy: Drug having disease-modifying potential will earn 40% patient share in the U.S

Fresenius Medical Care fourth-quarter net revenue up 12%

Nominations accepted for 2010 George Washington Carver Award

Emerging oral atypical antipsychotics to compete in increasingly crowded schizophrenia drug market

Sentry BioPharma Services to warehouse and distribute influenza vaccines for CDC

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

FEHBP PBM contracts: HR 4489 to reduce fraud and grant OPM greater power to audit

PAREXEL International expands capabilities by opening new early phase unit in Port Elizabeth, South Africa

UK pharmacists overwhelmingly prefer dispensing preservative-free drugs

Poniard Pharmaceuticals enters into $20M committed equity financing facility with Commerce Court Small Cap Value Fund

Medical innovation: A real boon for American patients

Watson Pharmaceuticals' fourth-quarter net revenue rises 22%

Tenet Healthcare announces 9.0% increase in fourth-quarter EBITDA

CellCentric out-licenses development, commercialisation of novel epigenetic discovery programme to Takeda Pharmaceutical

WuXi PharmaTech's Shanghai c-GMP manufacturing facility receives MPA compliance certificate

Clout of drug industry seen in MD residency programs and in health reform

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence